KRAS and acute myeloid leukemia: ExomiR-217 sensitizes AML to doxorubicin via targeting KRAS (Xiao et al., 2017) while exomiR-143 enhances chemosensitivity of AML to cytosine arabinoside by targeting ATG7-and ATG2B-dependent autophagy (Zhang et al., 2020a).